HCPCS code J7999: Compounded drug, not otherwise classified

Key Takeaways

HCPCS Code J7999 covers compounded drugs that have no specific HCPCS J-code, added to the code set effective January 1, 2016.

Use J7999 only after confirming no specific J-code exists for the compounded drug – it carries Coverage Code D, meaning special coverage instructions apply.

J7999 is paid by invoice for most compounded drugs; the exception is intravitreal bevacizumab (Avastin), which follows a separate MAC-specific payment methodology.

Every J7999 claim requires a narrative in Box 19 of the CMS-1500 form – claims submitted without a drug name, dose, and route of administration are routinely denied.

Compounded (repackaged) bevacizumab bills under J7999, but the manufactured product uses a different code – J9035 for Avastin or the matching Q-code for a biosimilar like Mvasi or Zirabev.

HCPCS Code J7999 is a billable code for a compounded drug, not otherwise classified – a medication custom-prepared by a pharmacy that has no specific HCPCS J-code and no National Drug Code (NDC). It was added to the HCPCS Level II code set on January 1, 2016, and carries Coverage Code D, meaning special coverage instructions apply.

The most common use is compounded bevacizumab (Avastin) for intravitreal injection, but J7999 covers any compounded drug that lacks a dedicated code. This guide covers when to use it, the documentation it requires, how it is reimbursed, and how it differs from related codes such as J3490 and J9999. For broader context on how these codes fit the claims process, see our overview of medical billing.

Code definition and properties

Compounded medications are custom-prepared by a pharmacist for an individual patient, so they carry no NDC and the standard J-code lookup does not apply. J7999 exists for exactly this situation. Its official long descriptor is “Compounded drug, not otherwise classified” and its short descriptor is “Compounded drug, noc.” Key administrative properties confirmed across CMS and MAC databases are listed below.

Coverage Code D is significant. It means Medicare does not automatically cover every compounded drug billed under J7999. Coverage decisions depend on the specific drug, the clinical indication, and the Medicare Administrative Contractor (MAC) with jurisdiction over the claim. Providers should verify MAC-specific policies before submitting.

When to use J7999 for compounded drugs

J7999 applies when a provider administers a compounded drug and no other HCPCS J-code accurately describes the medication. The controlling rule is straightforward: if no HCPCS code exists for the compound being billed, J7999 is the appropriate code to use. Payers and MACs state this explicitly in their drugs and biologicals guidance.

The most common clinical scenario is intravitreal bevacizumab, marketed as Avastin but compounded by a pharmacy for injection into the eye. Because compounded bevacizumab has no NDC, a specific J-code cannot be assigned. A Novitas LCD article referenced by the American Academy of Ophthalmology confirms that providers should report J7999 for compounded bevacizumab administered intravitreally.

Other situations where J7999 applies include compounded pain management solutions, custom hormone preparations, and off-label compounded biologics administered in-office. The Avastin rule only holds when a pharmacy has actually repackaged or altered the product – if the manufacturer’s labeled bevacizumab is administered as supplied, a different code applies (see the comparison below). The decision logic for J7999 itself is straightforward:

• Is the drug compounded by a pharmacy for an individual patient? If yes, proceed to the next step.
• Does a specific HCPCS J-code exist for this drug? If no, use J7999.
• Is the drug a chemotherapy or antineoplastic agent? If yes, use J9999 instead – J7999 excludes antineoplastic drugs by definition.
• Is it administered through durable medical equipment (DME)? If yes, consider J7699 (inhalation solutions via DME) or J7799 (non-inhalation drugs via DME) before defaulting to J7999.

The same disciplined code-selection logic applies to any injectable drug billed under HCPCS – see, for example, the HCPCS Code J3480 billing guide for how a specific, classified drug code is handled by comparison.

J7999 vs related NOC drug codes: a decision guide

Several HCPCS codes cover unclassified or not-otherwise-classified drugs. Choosing the wrong one is one of the most frequent denial triggers in compounded drug billing. The table below maps the key distinctions confirmed by CMS HCPCS guidance and MAC billing articles.

The most common source of confusion is J7999 vs J3490. The critical distinction: J3490 covers commercially manufactured drugs with no specific J-code; J7999 is reserved for compounded drugs specifically. Because compounded medications lack an NDC by definition, standard J-codes cannot be applied, and J7999 becomes the correct route.

J7999 vs J9035: compounded vs manufactured bevacizumab

Bevacizumab is one drug with several possible billing codes, and the correct one depends entirely on what the pharmacy did to it before it reached the patient. J7999 applies only when a compounding pharmacy has repackaged or altered the product – typically splitting a full-size vial into single-dose intravitreal aliquots for multiple patients, which is why many ophthalmology practices use a compounding pharmacy for Avastin in the first place.

If the manufacturer’s labeled product is billed as supplied, without compounding, a different code applies instead of J7999:

• J9035 – brand-name Avastin (bevacizumab), billed per 10 mg
• Q5107 – Mvasi, a bevacizumab biosimilar
• Q5118 – Zirabev, a bevacizumab biosimilar
• Q5126 – Alymsys, a bevacizumab biosimilar
• Q5129 – Vegzelma, a bevacizumab biosimilar

NGS Medicare’s billing and coding article for bevacizumab and biosimilars confirms this split. Billing J9035 or a Q-code for a compounded product – or J7999 for a manufactured one administered as labeled – is a frequent, avoidable denial trigger.

Practices billing across multiple payer types, including private payers and Medicare, often need to map different NOC codes to the same drug depending on the patient’s coverage. Building a payer-specific code reference into your billing workflow avoids this confusion at claim time.

Documentation requirements when billing J7999

J7999 claims are denied more often than most drug codes because payers require supporting narrative and documentation that standard J-codes do not require. Coverage Code D signals this directly: special coverage instructions apply, and the provider must supply the specifics.

Box 19 narrative on the CMS-1500 form

Every J7999 claim submitted on a CMS-1500 form must include a narrative description in Box 19. At minimum, the narrative should include:

• Drug name: the generic name of the compounded drug (e.g., “bevacizumab compounded for intravitreal injection”)
• Dose: the total dose administered per unit billed (e.g., “1.25 mg / 0.05 mL”)
• Route of administration: injection site or method (e.g., “intravitreal injection”)
• NDC notation: a statement that no NDC exists because the drug is compounded

Electronic claim submissions use the narrative equivalent field. Some MACs also require the compounding pharmacy’s invoice to be submitted alongside the claim. Check your specific MAC’s billing article before submitting.

Medical record documentation

The patient’s medical record must support the medical necessity of the compounded drug. Required elements include the diagnosis justifying administration, documentation that no commercially available alternative was clinically appropriate, and a record of the drug name, dose, date, and administering provider.

For ophthalmology practices billing compounded bevacizumab under J7999, Novitas and other MACs require documentation aligning with the relevant LCD for intravitreal anti-VEGF therapy. Capturing this on a structured superbill at the point of care prevents reconstruction errors at billing time.

Structured digital documentation workflows help ensure that clinical notes capture the required drug administration details at the point of care, rather than reconstructing them at billing time. Practices using prescription management workflows can tag compounded prescriptions for automatic documentation flags.

Modifiers required on J7999 claims

J7999 is typically billed from a single-dose container, which brings CMS’s drug-wastage modifiers into play alongside the Box 19 narrative:

• JW: reports any unused, discarded portion of a single-dose vial. Required since 2017, and the discarded amount must also be documented in the medical record.
• JZ: confirms there was no discarded amount. Mandatory on Medicare Part B claims for single-dose drugs since July 1, 2023 – claims missing JW or JZ where one applies can be returned unprocessed.
• RT / LT: for intravitreal injections, report the treated eye. Use both only when each eye is treated in the same encounter with separate documentation.

Omitting JW or JZ is an easy way to turn an otherwise clean J7999 claim into a denial, since it now sits alongside the Box 19 narrative as a standard documentation check.

Automate compounded drug documentation before claims go out

Pabau's claims management tools help practices capture drug name, dose, and administration details at the point of care – so J7999 narratives are ready before billing, not assembled from memory after a denial.

Book a demo

J7999 Medicare reimbursement rules

J7999 Medicare reimbursement rules start with Part B, which covers drugs administered incident to a physician’s service – compounded drugs can qualify, but coverage is not guaranteed. Two reimbursement methodologies apply depending on the specific drug billed under J7999.

Invoice-based payment (most compounded drugs)

For the majority of compounded drugs billed under J7999, Medicare pays based on the provider’s invoice from the compounding pharmacy. According to FCSO Medicare’s guidance on not-otherwise-classified codes, J7999 is “paid by invoice except for Intravitreal Avastin.” This means the reimbursement amount is not published in the Medicare Physician Fee Schedule (MPFS) – it is determined by the actual acquisition cost documented on the pharmacy invoice.

To support invoice-based payment, providers should retain the compounding pharmacy invoice and submit it with the claim when required. Some MACs require invoice submission proactively; others request it on appeal. Confirm your MAC’s process through its billing articles or provider portal.

Intravitreal bevacizumab: a separate payment path

Compounded bevacizumab (Avastin) for intravitreal injection follows a different reimbursement approach. Because of its volume and consistent use in ophthalmology, several MACs have established specific payment rates rather than relying on invoice. The Novitas LCD confirms J7999 as the correct code, but payment is set by MAC-specific local coverage policy rather than invoice alone. Practices billing this drug should review the current Novitas or regional MAC billing article for the applicable rate and any prior authorization requirements.

Prior authorization and medical necessity

Medicare does not uniformly require prior authorization for J7999, but individual MACs may. Commercial payers and state Medicaid programs have their own requirements. Always verify authorization requirements for the specific drug and payer before administration. Failure to obtain required authorization is one of the leading causes of J7999 denials that cannot be successfully appealed.

For practices building revenue cycle workflows across multiple payer types, adding prior authorization checks to the pre-service step prevents the most avoidable denials. Confirm whether a fee schedule rate exists for J7999 under your MAC’s jurisdiction before relying on invoice pricing, since most compounded drugs are contractor-priced rather than listed in the fee schedule.

Claim submission workflow for J7999

Submitting a clean J7999 claim requires more preparation than most drug codes. The following step-by-step workflow reflects the requirements confirmed by NGS Medicare, Noridian, and FCSO billing guidance.

1. Confirm the drug is compounded – verify with the compounding pharmacy that the medication has no NDC. Non-compounded drugs with no J-code should be billed under J3490, not J7999.
2. Confirm no specific J-code exists – search the current HCPCS Level II code set for the drug. If a specific code exists, use it instead of J7999.
3. Check for chemotherapy classification – if the drug is antineoplastic, route to J9999 instead.
4. Obtain the compounding pharmacy invoice – record the drug name, dose, date compounded, and acquisition cost.
5. Document the clinical indication – the patient record must support medical necessity before the claim is submitted, not after a denial.
6. Complete Box 19 narrative – include drug name, dose per unit billed, route of administration, and a note that no NDC exists.
7. Submit the claim with supporting documentation – attach the invoice if your MAC requires it upfront. Retain all documentation regardless.

For practices handling compounded drug billing alongside other unclassified codes, a consistent internal checklist for J7999 claims cuts denial rates significantly. The same documentation discipline that applies to specialty drug billing codes in reproductive medicine applies here: narrative specificity and invoice documentation are the difference between clean claims and lengthy appeals.

Practices that have built structured billing workflows – the same rigor they apply to drug administration billing – consistently report fewer initial denials than those handling J7999 claims on an ad hoc basis.

Common denial reasons and how to prevent them

J7999 denials fall into predictable patterns. Each has a straightforward prevention strategy.

• Missing Box 19 narrative: The most common denial. Submit every J7999 claim with a complete narrative – drug name, dose, route, and NDC statement – every time.
• Wrong code selected: Using J7999 for a commercially manufactured drug (correct code: J3490) or an antineoplastic compound (correct code: J9999) triggers automatic denial. Confirm the drug classification before coding.
• No medical necessity documentation: The patient’s clinical record must support why a compounded preparation was necessary instead of a commercially available alternative. Document this reasoning in the encounter note.
• Invoice not retained or not submitted: MACs paying by invoice will deny claims without supporting cost documentation. Collect the pharmacy invoice before submission.
• Prior authorization not obtained: Some commercial plans and state Medicaid programs require prior authorization for compounded drugs. Check payer requirements before drug administration.

For practices managing drug inventory management alongside billing workflows, linking compounded drug records to claim documentation at the point of dispensing reduces the manual reconstruction work that leads to denial-prone claims. Maintaining HIPAA-compliant documentation practices throughout the compounded drug workflow also protects practices during audit.

When a denial is received, appeal promptly. Most J7999 denials are not coverage decisions – they are administrative deficiencies. A well-documented appeal with the compounding pharmacy invoice, Box 19 narrative, and clinical notes resolves the majority of cases on first reconsideration.

Conclusion

Compounded drug billing fails most often not because of coverage issues, but because of preventable documentation errors. HCPCS Code J7999 requires a complete Box 19 narrative, a compounding pharmacy invoice, and clinical notes supporting medical necessity – every time, on every claim. The right medical billing software makes that documentation routine rather than reactive.

Pabau’s claims management software connects point-of-care drug administration records directly to billing workflows, so the documentation required for clean J7999 submissions is captured before a claim is ever generated. To see how Pabau handles compounded drug billing documentation end to end, book a demo.

Continue your research

Need a structured approach to procedure code billing? Bupa procedure codes fee schedule covers how private payer procedure billing works across the major insurers.

Looking for guidance on other unclassified billing codes? Pabau claims management tracks NOC code submissions and prior authorization status across your full payer mix.

Managing multiple drug types across specialties? Pabau for functional medicine practices includes documentation and billing support for compounded and specialty drug protocols.

Frequently asked questions